1-methyl-3R-phenyl-pyrrolidine | 750584-06-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-methyl-3R-phenyl-pyrrolidine
• 英文别名: (R)-1-Methyl-3-phenylpyrrolidine；(3R)-1-methyl-3-phenylpyrrolidine
• CAS: 750584-06-6
• 化学式: C₁₁H₁₅N
• 分子量: 161.247
• InChiKey: YDNBZEZHOYJIKQ-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  聚合甲醛 、 (R)-3-苯基吡咯烷 以 甲酸 、 水 为溶剂， 反应 1.5h， 以100%的产率得到1-methyl-3R-phenyl-pyrrolidine
  参考文献：
  名称：

  [EN] N-HETEROCYCLYL-SUBSTITUTED AMINO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS
  [FR] DERIVES D'AMINO-THIAZOLE SUBSTITUES PAR N-HETEROCYCLYLE EN TANT QU'INHIBITEURS DE LA PROTEINE KINASE

  摘要：

  Aminothiazole化合物在2-氨基位置带有N-含氮环烷基，其化学式表示为（I），或者该化合物的药学上可接受的前药，或者该化合物的药学上可接受的盐，可以调节和/或抑制细胞增殖和蛋白激酶活性。

  公开号：

  WO2004074283A1

文献信息

• N-containing cycloalkyl-substituted amino-thiazole derivatives and pharmaceutical compositions for inhibiting cell proliferation and methods for their use
  申请人：Chu Shao Song

  公开号：US20050101595A1

  公开（公告）日：2005-05-12

  Aminothiazole compounds with N-containing cycloalkyl at the 2-amino position which are represented by the Formula (I), or a pharmaceutically acceptable prodrug of said compound, pharmaceutically active metabolite or pharmaceutically acceptable salt of said compound, or metabolite thereof, modulate and/or inhibit the cell proliferation and activity of protein kinases. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating malignancies and other disorders by administering effective amounts of such compounds.

  公式（I）所代表的在2-氨基位置带有含氮环烷基的氨基噻唑化合物，或该化合物的药物可接受的前药、药理活性代谢物或药物可接受的盐，或其代谢物，可以调节和/或抑制蛋白激酶的细胞增殖和活性。本发明还涉及含有这种化合物的制药组合物的治疗或预防用途，以及通过给予这种化合物的有效量来治疗恶性肿瘤和其他疾病的方法。
• AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF
  申请人：Sugasawa Keizo

  公开号：US20100249088A1

  公开（公告）日：2010-09-30

  [Object] To provide a therapeutic and/or prophylactic agent for urinary frequency, urinary urgency, and urinary incontinence associated with various lower urinary tract diseases including overactive bladder, various lower urinary tract diseases accompanied by lower urinary tract pain, such as interstitial cystitis, chronic prostatitis, and the like, and various diseases accompanied by pain, based on an excellent trkA receptor inhibitory action. [Means for Solution] A novel azolecarboxamide compound in which a thiazole ring or an oxazole ring is bonded to a benzene ring, a pyridine ring, a pyridazine ring, a thiophene ring, a pyrazole ring or a pyrrole ring through carboxamide, or a salt thereof is confirmed to have a potent trkA receptor inhibitory activity, and found to be capable of being used as a therapeutic and/or prophylactic agent which is excellent in efficacy and safety for urinary frequency, urinary urgency, and urinary incontinence associated with various lower urinary tract diseases including overactive bladder, various lower urinary tract diseases accompanied by lower urinary tract pain, such as interstitial cystitis, chronic prostatitis, and the like, and various diseases accompanied by pain, thereby completing the present invention.

  [目的] 提供一种治疗和/或预防下尿道疾病引起的尿频、尿急和尿失禁的治疗剂和/或预防剂，包括膀胱过度活动、伴有下尿道疼痛的各种下尿道疾病，如间质性膀胱炎、慢性前列腺炎等，以及伴有疼痛的各种疾病，基于出色的trkA受体抑制作用。 [解决方案] 发现一种新型的唑类羧酰胺化合物，其中一种噻唑环或噁唑环通过羧酰胺键与苯环、吡啶环、吡嗪环、噻吩环、吡唑环或吡咯环结合，或其盐具有强效的trkA受体抑制活性，并发现它能够被用作治疗和/或预防剂，对于包括膀胱过度活动、伴有下尿道疼痛的各种下尿道疾病，如间质性膀胱炎、慢性前列腺炎等，以及伴有疼痛的各种疾病，具有出色的疗效和安全性，从而完成了本发明。
• N-HETEROCYCLYL-SUBSTITUTED AMINO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS
  申请人：PFIZER INC.

  公开号：EP1597256A1

  公开（公告）日：2005-11-23
• NOVEL COMPOUNDS THAT ARE ERK INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2900241B1

  公开（公告）日：2018-08-08
• FUNCTIONALIZED PYRROLIDINES AND USE THEREOF AS IAP INHIBITORS
  申请人：Laurent Alain

  公开号：US20110117081A1

  公开（公告）日：2011-05-19

  A compound of Formula (1) or a salt thereof, methods for the preparation and use of such a compound, especially as an IAP inhibitor, and related compounds, compositions, and methods.